What is medical affairs? Launch and Lifecycle?
How has this area evolved over the last 2 decades?
What is the current state across the industry in terms of the role of statistics in this space?
This is a series of episodes and today’s content is the first episode. Join Jenny and I while we dive into her career and discuss important points about the following:
[Read more…] about What is the current state of Launch and Lifecycle work and how did it evolve?When there is one topic, which is really hot, it’s causal inference. I’ve got in contact with it about 20 years ago when analysing observational studies and when nobody working on clinical trials would consider it. But now – after the introduction of the estimands framework – this becomes part of every statisticians toolkit. Today, we have one of the world leading experts in this field as a guest – Miguel Hernan. I’m talking with him about:
What is casual inference?
How can this help generate and analyze data to identify better strategies for the treatment and prevention of both infectious and noninfectious diseases?
In today’s episode, we will be diving deep into this interesting topic and talk specifically about the following:
[Read more…] about The best of causal inferenceThe guest in this episode represents the sponsor of this show – Nigel Howitt – current chair of PSI.
After a short introduction of Nigel and his experience with PSI, we will cover the following topics:
[Read more…] about Replay of How to get the most out from your PSI membershipIn the modern workplace, conflict has become a difficult topic. After all, conflict is antithetical to teamwork, employee engagement, and a positive company culture. Or is it?
“No” is a sign of conflict and many avoid saying it by all means. But…
Why is saying no so hard?
How do we say no in the right way?
When should we say no?
In this episode, Liane Davey, who is the author of the book “The Good Fight”, and I will be discussing about how to say no effectively. I met her on Linkedin and we had a couple of messages and it was just really cool that we think the same way. Stay tuned because you’ll surely love it!
We discuss about the following points:
[Read more…] about How to say NOSubgroup analyses in combination with data visualisation is one of the hottest topics I can think about. And it hits us as statisticians during our careers again and again.
We need to understand subgroups for efficacy reasons and safety reasons and it’s a common question in terms of how consistent your drug works across the different subgroups. It gets even more complicated if you want to review it across multiple studies.
In this episode, Paolo and I discuss the importance of visualisation in understanding subgroups. Specifically we speak about:
[Read more…] about How to analyse subgroups effectively using data visualisationPublishing data is great, but we also want to measure the impact our work has beyond the additional entry in our CVs. During this episode, Mike and I discuss the tools Altmetric and Dimensions. These can help us to understand the reach and influence of clinical and scientific research beyond citations. Based on these, we can track the full journey, from idea to impact.
We touch on a number of interesting topics during the interview, including how Altmetric and Dimensions work together in uncovering this journey, but also the insights that can be gleaned from the kind of data the tools provide.
‘I get to sit in the middle of this wonderful web with both Dimensions data and altmetric and I pull the two things together. And together, I can create these translational maps of where research is going from the laboratory through to the hospital and into the broader population.’ – Mike Taylor
The discussion also touches on:
[Read more…] about Measuring the impact of our research via data science on data
